Interleukin-6 Trans-signaling: A Pathway With Therapeutic Potential for Diabetic Retinopathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Protective Efficacy of Selenium in Cisplatin-Induced Retinal Toxicity: An Experimental Immunohistochemical and Ultrastructural Analysis.Nutrients · 2026
   Article
2. Mechanisms and applications of natural plant ingredients in modulating amino acid metabolism for the improvement of diabetic retinopathy: a review.Frontiers in endocrinology · 2026
   Review
3. The role of interleukin-6 in diabetic retinal disease: pathophysiology and therapeutic targeting.Frontiers in immunology · 2026
   Review
4. Exerkines in diabetic retinopathy: from mechanisms to therapeutic prospects.Frontiers in endocrinology · 2026
   Review
5. Secreted IgM deficiency alters the retinal landscape enhancing neurodegeneration associated with aging.Immunity & ageing : I & A · 2025
   Article
6. Inflammatory mechanisms in diabetic retinopathy: pathogenic roles and therapeutic perspectives.American journal of translational research · 2025
   Review
7. Network Pharmacology and Molecular Docking to Explore the Mechanism of Compound Qilian Tablets in Treating Diabetic Retinopathy.Current computer-aided drug design · 2025
   Article
8. The multifaceted role of vitreous hyalocytes: Orchestrating inflammation, angiomodulation and erythrophagocytosis in proliferative diabetic retinopathy.Journal of neuroinflammation · 2024
   Article
9. Cytokine Levels in Experimental Branch Retinal Vein Occlusion Treated With Either Bevacizumab or Triamcinolone Acetonide.Translational vision science & technology · 2024
   Article
10. Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms.Antioxidants (Basel, Switzerland) · 2024
    Review
11. IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization.Frontiers in immunology · 2024
    Article
12. Interleukin-6 and Macular Edema: A Review of Outcomes with Inhibition.International journal of molecular sciences · 2023
    Review
13. Diabetic complications and prospective immunotherapy.Frontiers in immunology · 2023
    Review
14. Deletion of NADPH oxidase 2 attenuates cisplatin-induced acute kidney injury through reducing ROS-induced proximal tubular cell injury and inflammation.Frontiers in medicine · 2023
    Article
15. The Ameliorative Effect of Thymoquinone on Vincristine-Induced Peripheral Neuropathy in Mice by Modulating Cellular Oxidative Stress and Cytokine.Life (Basel, Switzerland) · 2022
    Article
16. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications.Cells · 2022
    Review
17. TGFβ1 Induces Senescence and Attenuated VEGF Production in Retinal Pericytes.Biomedicines · 2022
    Article
18. The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications.Frontiers in immunology · 2022
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as